Datopotamab Deruxtecan + Rilvegostomig + Carboplatin + Cisplatin + Etoposide + Pemetrexed + Vinorelbine + UFT
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Oct 15, 2024 → Jun 30, 2027
NCT ID
NCT06564844About Datopotamab Deruxtecan + Rilvegostomig + Carboplatin + Cisplatin + Etoposide + Pemetrexed + Vinorelbine + UFT
Datopotamab Deruxtecan + Rilvegostomig + Carboplatin + Cisplatin + Etoposide + Pemetrexed + Vinorelbine + UFT is a phase 3 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06564844. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06564844 | Phase 3 | Active |
Competing Products
20 competing products in Non-small Cell Lung Cancer